S. 41: Medicare Prescription Drug Price Negotiation Act of 2017 - Provisions related to Part D and drug pricing negotiation
S. 251: Protecting Medicare from Executive Action Act of 2017 - Provisions related to repeal of the Independent Payment Advisory Board (IPAB)
S. 260: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB
H.R. 242:  Medicare Prescription Drug Price Negotiation Act of 2017 - Provisions related to Part D and drug pricing negotiation
H.R. 849: Protecting Seniors' Access to Medicare Act of 2017 - Provisions related to repeal of the IPAB
H.J.Res. 51 - Approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
S.J.Res. 16 - A joint resolution approving the discontinuation of the process for consideration and automatic implementation of the annual proposal of the Independent Medicare Advisory Board under section 1899A of the Social Security Act - Provisions related to the IPAB repeal
Part D policy issues including non-interference and rebates policy issues
Drug cost and pricing policy issues
Center for Medicare and Medicaid Innovation (CMMI) transparency and other policy issues U.S. Trade policy, including IP and pharmaceutical market access issues
Japan Pricing and Regulatory Issues
U.S. IP policy at multilateral organizations
Philippine Potential Compulsory Licensing Issue Senate and House Committee Tax Reform Proposals
Puerto Rican Economy and Debt Relief Proposals
Proposals to reform domestic and international tax structures S.Con.Res 3: Budget Resolution - Provisions related to the biopharmaceutical industry including importation and non-interference S. 124: Preserve Access to Affordable Generics Act - Provisions related to patent settlements
Biopharmaceutical innovation and patent policy issues
Bayh-Dole march-in rights policy issues S. 64: Safe and Affordable Drugs from Canada Act of 2017 - Provisions related to importation
S. 92: Safe and Affordable Drugs from Canada Act of 2017 - Provisions related to importation 
S. 204: Trickett Wendler Right to Try Act of 2017 - Provisions related to use of unapproved medical products by patients with a terminal illness
S. 456: RACE for Children Act - Provisions related to pediatric studies
S. 469: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation
S. 771: Improving Access to Affordable Prescription Drugs Act - Provisions related to drug pricing 
H.R. 749: Lower Drug Costs Through Competition Act - Provisions related to generic drug 
approvals and priority review vouchers
H.R. 820: Childhood Cancer STAR Act - Provisions related to expanded access and other policy issues
H.R. 878: Right to Try Act of 2017 - Provisions related to use of unapproved medical products by patients with a terminal illness
H.R. 1231: RACE for Children Act - Provisions related to pediatric studies
H.R. 1245: Affordable and Safe Prescription Drug Importation Act - Provisions related to importation
H.R. 1480: Safe and Affordable Drugs from Canada Act of 2017 - Provisions related to importation
H.R. 1628: American Health Care Act of 2017 - Provisions related to the biopharmaceutical industry including repeal of brand pharmaceutical manufacturer fee and individual and employer mandates, insurance affordability provisions, and Medicaid reforms
H.R. 1776: Improving Access to Affordable Prescription Drugs Act - Provisions related to drug pricing
Prescription Drug User Fee Act (PDUFA) reauthorization
Biologics User Fee Act (BsUFA) reauthorization
340B drug discount program policy issues
Orphan Drug Act policy issues
Biologics Price Competition and Innovation Act (BPCIA) implementation issues
Patient assistance program policy issues
MMM - Medicare/Medicaid TRD - Trade (domestic/foreign) TAX - Taxation/Internal Revenue Code BUD - Budget/Appropriations CPT - Copyright/Patent/Trademark HCR - Health Issues
136 - Centers For Medicare and Medicaid Services (CMS) 24 - Commerce, Dept of (DOC) 34 - Health & Human Services, Dept of (HHS) 137 - Health Resources & Services Administration (HRSA) 2 - HOUSE OF REPRESENTATIVES 253 - Medicare Payment Advisory Commission (MedPAC) 113 - Patent & Trademark Office (PTO) 1 - SENATE 39 - State, Dept of (DOS) 22 - U.S. Trade Representative (USTR) 136 - Centers For Medicare and Medicaid Services (CMS) 24 - Commerce, Dept of (DOC) 34 - Health & Human Services, Dept of (HHS) 137 - Health Resources & Services Administration (HRSA) 2 - HOUSE OF REPRESENTATIVES 253 - Medicare Payment Advisory Commission (MedPAC) 113 - Patent & Trademark Office (PTO) 1 - SENATE 39 - State, Dept of (DOS) 22 - U.S. Trade Representative (USTR) 136 - Centers For Medicare and Medicaid Services (CMS) 24 - Commerce, Dept of (DOC) 34 - Health & Human Services, Dept of (HHS) 137 - Health Resources & Services Administration (HRSA) 2 - HOUSE OF REPRESENTATIVES 253 - Medicare Payment Advisory Commission (MedPAC) 113 - Patent & Trademark Office (PTO) 1 - SENATE 39 - State, Dept of (DOS) 22 - U.S. Trade Representative (USTR) 136 - Centers For Medicare and Medicaid Services (CMS) 24 - Commerce, Dept of (DOC) 34 - Health & Human Services, Dept of (HHS) 137 - Health Resources & Services Administration (HRSA) 2 - HOUSE OF REPRESENTATIVES 253 - Medicare Payment Advisory Commission (MedPAC) 113 - Patent & Trademark Office (PTO) 1 - SENATE 39 - State, Dept of (DOS) 22 - U.S. Trade Representative (USTR) 136 - Centers For Medicare and Medicaid Services (CMS) 24 - Commerce, Dept of (DOC) 34 - Health & Human Services, Dept of (HHS) 137 - Health Resources & Services Administration (HRSA) 2 - HOUSE OF REPRESENTATIVES 253 - Medicare Payment Advisory Commission (MedPAC) 113 - Patent & Trademark Office (PTO) 1 - SENATE 39 - State, Dept of (DOS) 22 - U.S. Trade Representative (USTR) 136 - Centers For Medicare and Medicaid Services (CMS) 24 - Commerce, Dept of (DOC) 34 - Health & Human Services, Dept of (HHS) 137 - Health Resources & Services Administration (HRSA) 2 - HOUSE OF REPRESENTATIVES 253 - Medicare Payment Advisory Commission (MedPAC) 113 - Patent & Trademark Office (PTO) 1 - SENATE 39 - State, Dept of (DOS) 22 - U.S. Trade Representative (USTR)
ABBVIE, INC.
1399 New York Avenue NW, Suite 600, Washington, DC, 20005, US
JOHN P. FORD HEATHER STRAWN STEPHEN SCANGO DANIEL BACHNER HEATHER STRAWN HEATHER STRAWN JOHN P. FORD DANIEL BACHNER STEPHEN SCANGO JOHN P. FORD HEATHER STRAWN DANIEL BACHNER STEPHEN SCANGO HEATHER STRAWN DANIEL BACHNER STEPHEN SCANGO JOHN P. FORD HEATHER STRAWN STEPHEN SCANGO DANIEL BACHNER